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Background: Frozen thawed embryo transfer (FET) is a cost- effective adjunct to IVF or IVF-ICSI treatment. In order
to optimize treatment outcome, FET should be carried out during a period of optimal endometrial receptivity. To
optimize implantation several methods for endometrium preparation have been proposed. In natural cycle FET
(NC-FET), the endometrium develops under endogenous hormonal stimulation. The development of the dominant
follicle and endometrium is monitored by ultrasound and FET is timed after triggering ovulation induction or
determination of the spontaneous LH surge. In an artificial cycle FET (AC-FET) estrogens and progesterone are
administered to prepare the endometrium for implantation. While the currently available data show no significant
difference in pregnancy rates between these methods, well designed randomized controlled trials are lacking.
Moreover there is little literature on difference in cancellation rates, cost-efficiency and adverse events.
Methods and design: In this randomized, multi-centre, non-inferiority trial we aim to test the hypothesis that there
is no significant difference in live birth rates between patients undergoing NC-FET versus AC-FET. The primary
outcome will be live birth rate per embryo transfer procedure. Secondary outcomes will be ongoing and clinical
pregnancy rate, cancellation rate, (serious) adverse events and cost-efficiency. Based on a live birth rate of 20% and
a minimal clinical important difference of 7,5% (one-sided alpha 2,5%, beta 20%) a total of 1150 patients will be
needed. Analyzes will be performed using both per protocol as well as intention to treat analyses.
Discussion: This prospective, randomized, non –inferiority trial aims to address the hypothesis that there is no
significant difference in live birth rates between patients undergoing NC-FET versus patients undergoing AC-FET.
Moreover it addresses cost-efficiency as well as the perceived burden of both treatments.
Trial register: Netherlands trial register (NTR): 1586Background
In Vitro Fertilization (IVF) or Intra Cytoplasmatic Sperm
Injection (ICSI) treatment cycles often produce more
embryos than can be transferred during the fresh treat-
ment cycle. Moreover, in some patients embryo transfer is
postponed for medical reasons (e.g. ovarian hyperstimula-
tion syndrome). Cryopreservation of these embryos pro-
vides both physicians and patients a safe, successful and
presumably cost-efficient option [1-3]. Recent develop-
ment and implementation of single embryo transfer strat-
egies in IVF and IVF -ICSI programs has increased the
importance of successful frozen thawed embryo transfer* Correspondence: e.r.groenewoud@umcg.nl
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distribution, and reproduction in any medium(FET) programs. Critical for a successful FET program is
synchronization between the endometrial development
and the embryo [4-7]. To achieve this, FET requires exten-
sive preparation, timing and planning. In recent years, sev-
eral methods for endometrium preparation have been
developed.
In natural cycle FET (NC-FET) planning of embryo
thawing and transfer requires the identification of a period
of optimal receptivity [4-7]. This putative ‘window of
implantation’ starts shortly after ovulation. If an embryo is
transferred within this window, the chances of conceiving
are greater [4-6]. Planning NC-FET can either be done
based on recognition of the LH surge that precedes ovula-
tion (using serum or urine LH monitoring) or by tri-
ggering ovulation (sometimes referred to as modifiedentral Ltd. This is an Open Access article distributed under the terms of the
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the dominant follicle is closely monitored by regular ultra-
sonic evaluation. On reaching a diameter of 16-20 mm
human chorionic gonadotrophin (hCG) is administered
and ovulation takes place approximately 36 h later.
Embryo thawing and transferring can be planned accord-
ingly. Despite ultrasonic monitoring, spontaneous ovula-
tions do occur. In such an event the start of the window of
implantation cannot be estimated accurately. Since identi-
fication of the onset of the window of implantation
is mandatory for further timing of FET, cycles with spon-
taneous ovulation are usually cancelled. To minimize
cancellation, patients are required to visit their clinic
several times which is time consuming and expensive. In
NC-FET cycles, 5-6% of all patients have insufficient
development of the dominant follicle and/or endometrium
thickness and treatment has to be cancelled [8]. However,
a clear advantage of NC-FET is the fact that it does not
require patients to take medication for several weeks. In
summary, NC-FET has the advantage of not requiring
medication but this advantage is balanced against the need
for frequent ultrasonic evaluation of the dominant follicle,
the risk of unexpected ovulation and the risk of insuffi-
cient development of the endometrium and/or dominant
follicle. Due to these factors NC-FET is more difficult to
plan.
Because of the above mentioned disadvantages an arti-
ficial FET (AC-FET) has been developed. This treatment,
which was originally developed for patients undergoing
oocyte donation, was also found to be successful for
patients undergoing FET treatment [9]. During AC-FET
patients start with daily estrogens which are supplemen-
ted with progesterone when the endometrial thickness is
considered sufficient. Patients have to take these drugs
for several weeks. The main advantage of this treatment
is that it requires little ultrasonic monitoring and there-
fore is more easily scheduled placing less burden on
both patients and doctors agenda’s. More over, planning
thawing and transfer is flexible and can be performed
based on convenience. Some also claim that supplement-
ing estrogen reduces cancellation rates due to insuffi-
cient endometrium thickness compared to NC-FET. The
main disadvantages of AC-FET are possible side-effects
and higher risk of thrombo-embolic events [10,11].
In recent years several, retrospective, studies compar-
ing live birth rates in both NC-FET and AC-FET have
been published. Both Morovoz et al. and Chang et al.
concluded that NC-FET results in higher pregnancy
rates [12,13]. However, in a retrospective analysis of
1677 FET cycles, Givens et al. observed no difference in
pregnancy rates between NC-FET and AC-FET. Preg-
nancy rates did not differ significantly between both
groups [14]. These results were consistent with those of
others [15-17]. A recent Cochrane review on treatmentregimes in FET concluded that current evidence does
not demonstrate a significant difference in pregnancy
rates between these methods of endometrial preparation.
However, the authors highlighted the need for further a
well designed, adequately powered RCT [18].
To the best of our knowledge there is no literature on
available discerning which regimen patients prefer,
which has fewer side effects, or which is the most cost
effective [19]. If live birth rates indeed are equal in
NC-FET and AC-FET the perceived burden of both
treatments, convenience and cost-efficiency might be
important factors in choosing one of both options.
Methods and design
Study objective
When it comes to planning FET treatment several ques-
tions remain. Although retrospective trials found no
significant difference in pregnancy rates there is little lit-
erature on other aspects such as side-effects and cost-ef-
ficiency. This prospective, randomized, controlled trial
aims to address these questions. All patients participat-
ing in the ANTARCTICA trial will also be invited to fill
in questionnaires regarding the perceived burden of both
treatments. The protocol for this study (Penguin-study)
will be discussed separately.
Hypothesis
The hypothesis to be tested is that there is no significant
difference in live birth rates between NC-FET and AC-FET,
but that NC-FET is more cost effective. Since the expected
low incidence of serious adverse events we expect to find
no significant difference based on a type 1 error.
Study design
The ANTARCTICA trial is a multi-center, randomized
controlled trial, powered to demonstrate non-inferiority of
NC-FET in terms of the primary study end point. A recent
systemic review of current literature identified no other
RCTs addressing this subject. Several retrospective studies
have shown discrepant findings but pooling of the data
indicated no difference in pregnancy rates between
NC-FET and AC-FET. Since our hypothesis is that signifi-
cant difference in the primary study endpoint will not be
observed, but a difference in cost-efficacy in favour of the
NC-FET will be demonstrated, a non-inferiority design is
appropriate. The research team is blinded for the result of
the randomization (Figure 1).
Study population and recruitment
Patients participating in the ANTARCTICA trial are
between the age of 18 and 40 and are undergoing FET
after their 1st, 2nd or 3rd IVF or IVF-ICSI cycle for various
indications. They must all have ovulatory cycles between
Figure 1 Flowchart eligible patients.
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consent to participate in the study.
Those patients who have a known contra-indication or
allergy for oral estradiol or vaginally administered
micronized progesterone are not eligible. Patients with a
uterine anomaly are also excluded from participation.
Oocyte donation for any other than a genetic indication
is also an exclusion criterion.
Eligible patients are informed about the ANTARC-
TICA trial during intake by their physician prior to FET
cycle. A minimum reflection period of 5 days will be
offered. Eligible patients who wish to participate will be
randomized after providing written consent. If an eligible
patient declines participation, some basic characteristics
will be obtained to identify any significant selection bias.
Primary and secondary endpoints
The primary endpoint is live birth rate per FET. Second-
ary endpoints are cancellation rate, clinical pregnancy
rate, ongoing pregnancy rate (all per FET), endometrium
thickness during transfer and (serious) adverse events.
More over cost-efficiency calculations will be performed.
Participating hospitals
Both secondary and tertiary fertility clinics performing
IVF and IVF-ICSI treatment are invited to participate in
the ANTARCTICA trial. At present 15 Dutch fertility
clinics are actively enrolling patients. Two further clinics
will join, pending approval by their local ethics committee.
Randomization
Randomization is performed using a web based
randomization program, based on restricted randomization
with allocation clusters of alternating sizes. Allocation is
based on a 1:1 assignment. Stratification for the initial
treatment (IVF vs IVF-ICSI) is performed. Since live birthrates might differ between clinics, each clinic has its own
blinded allocation list.
Data collection
Data collection is performed using a web-based case
report form (electronic CRF or eCRF). Basic data on
patient’s general history and specific fertility history are
obtained from the out-patient clinic chart. Characteris-
tics of the initial treatment as well as characteristics of
the FET treatment are also noted.
For the cost-efficiency study patients are invited to




Patients allocated to intervention 1 will undergo their FET
in a natural cycle. Starting on day 10, 11 or 12 of their
cycle regular ultrasonic evaluation of the endometrium
thickness and mean diameter of the dominant follicle is
performed. When the endometrium is 6 mm or more and
the diameter of the dominant follicle is 16-20 mm a blood
sample is taken (for blinded analyses of progesterone and
LH levels) and ovulation is induced using hCG injection
(pregnyl 5000 IE, MSD USA or ovitrelle 250 μgram,
Serono Benelux bv, Germany). Thawing and transferring
is performed subsequently according to local protocols. A
maximum of two embryos will be transferred.
If during ultrasonic evaluation no follicle is visible
ovulation is deemed to have occurred. In this event no
thawing or transferring will take place. This cycle is
regarded a drop-out. Further treatment can be con-
ducted according to local protocols (Figure 2).
AC-FET (intervention 2)
If patients are allocated to intervention 2, an artificial
cycle FET will be performed. From day one of the cycle
Figure 2 Flowchart natural cycle.
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Germany) 2 mg three times daily. After 11, 12 or 13 days
an ultrasound is performed. If no leading follicle is present
and the endometrial thickness is≥ 8 mm, micronized pro-
gesterone (utrogestan Besins International, Belgium) is
added to the regime and thawing and transferring is com-
menced 4 or 5 days later according to the stage of cryo-
preservation [20].
If the endometrial thickness is less than 8 mm, the pro-
gynova dose is raised to 2 mg 4 times daily for 7 days.
After a week the endometrium is checked once again.
When the endometrium thickness is >8 mm and no dom-
inant follicle (≥ 14 mm) is present, utrogestan can be
added and thawing and transferring is performed accord-
ing to local protocols. A maximum of two embryos will be
transferred.
If a follicle is visible during ultrasound, serum
luteinizing hormone (LH) and progesterone levels are
determined. If these are raised, (serum LH ≥ 13 E/l or
progesterone ≥ 15 nmol/l) luteinization of the follicle is
considered to have taken place and because of the asso-
ciated diminished pregnancy rates, thawing and transfer-
ring will not be performed. If serum levels are below the
above mentioned levels thawing and transferring can be
performed according to local protocol (Figure 3).
Embryo quality is recorded according to study criteria.
These criteria can be used beside clinics’ own criteria.
The criteria for embryo quality are based on the consen-
sus between the largest participating centers.Statistical analysis
Sample size and power considerations
Live birth rates in FET treatment in the Netherlands are,
on average, 20% per cycle. The minimal clinical import-
ant difference (MCID) could not be based on literature
concerning FET treatment alone. Based on other studies
within fertility care a consensus of a MCID of 7,5% was
adapted. This clinical important difference compares to
a one sided hypothesis test with a 0.025% significance
level with a null hypothesis of AC-FET being inferior to
NC-FET. Using a two-sided alpha of 5% and 80% dis-
criminating capacity we calculated that 1150 patients
have to be enrolled in this study. All patients will partici-
pate with one cycle only.
Data analysis
Statistical analyses will be performed using a per proto-
col analyses. The primary endpoint in this study is live
birth rates in both treatments. Since intention-to-treat
analyses is more adequate for implementing the results
of this study in daily fertility practice such an analyses
will be performed also besides a per-protocol analysis.
Using logistic regression analysis confounding factors
will be analyzed. These factors include age during initial
treatment, duration of the subfertility, number and qual-
ity of the embryos transferred and outcome of initial
treatment. Selection of these criteria is based on current
opinion in literature [20-24]. A comparison of baseline
characteristics of enrolled patients with the baseline
Figure 3 Flowchart artificial cycle.
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be performed to exclude selection bias.
Secondary endpoints are clinical and ongoing preg-
nancy rates, cancellation rate, endometrium thickness
and (serious) adverse events. Most secondary endpoints
will be analyzed using a Fishers’ exact test; endometrium
thickness will be analyzed using a student t-test. Cost-
efficiency of both treatments will be calculated on the
ratio between differences in cost and live birth rates.
Ethics
This study is designed using the guidelines for good clin-
ical practice as well as the decleration of Helsinki. Ap-
proval was obtained from both national (CCMO) and
Medical Ethics Committee of the Isala Clinics in Zwolle.
For each participating hospital approval of the local
Medical Ethics Committee was requested. According the
GCP guidelines written informed consent prior to
randomization will be mandatory.
Discussion
With this study we aim to clarify whether NC-FET and
AC-FET do not differ significantly in live birth rates.Moreover we hope to provide some answers regarding
secondary endpoints and cost-efficiency.
The use of hCG in planning NC-FET remains a sub-
ject of debate. In recent years both randomized pro-
spective studies as well as retrospective studies have
been publicized with conflicting results. In this study
NC-FET based on ovulation induction was chosen after
careful considerations. There are several issues when
using LH determination for timing FET. (Groenewoud
et al., Reprod Biomed Online. 2012 Feb;24 (2):191–6)
Also there is no information on whether pregnancy rates
could be improved if we would adjust planning of thaw-
ing and transfer according to the presence of LH surge.
To the best of our knowledge, no such studies have been
conducted in patients undergoing ultrasound monitored
unstimulated cycle FET.
Due to the lack of literature in FET treatment some of
our decisions regarding study design and statistical ana-
lyses (e.g. MCID) had to be made based on IVF litera-
ture in general. With 15 clinics participating the actual
live birth rate might differ from clinic to clinic. Choosing
both an overall analyses as well as analyses per clinic the
authors hope to gain insight in this matter. Moreover
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ber of patients needed for sufficient statistical power. In
designing this study, careful consideration was therefore
required of the feasibility of meeting recruitment targets,
and what steps could be taken to limit obstacles to recruit-
ment. With these considerations, and the participation of
15 clinics, we consider this study to be achievable within
the planned time frame of 4 years.
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